Page last updated: 2024-11-08

rhapontin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

rhapontin: constituent of rhubarb rhizome [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID637213
CHEMBL ID109266
CHEBI ID8824
CHEBI ID92176
SCHEMBL ID160068
MeSH IDM0080900

Synonyms (62)

Synonym
BRD-K10098805-001-02-0
unii-k691m2z08v
rhapontigenin, 3-beta-d-glucopyranoside
k691m2z08v ,
glucopyranoside, rhapontigenin-3, beta-d-
nsc 43321
3-hydroxy-5-(2-(3-hydroxy-4-methoxyphenyl)vinyl)phenyl-beta-d-glucopyranoside
beta-d-glucopyranoside, 3-hydroxy-5-(2-(3-hydroxy-4-methoxyphenyl)ethenyl)phenyl
einecs 205-845-0
nsc-43321
ponticin
BSPBIO_002946
NCGC00178379-01
3-hydroxy-5-(2-(3-hydroxy-4-methoxyphenyl)ethenyl)phenyl-beta-d-glucopyranoside
IDI1_001004
SPECTRUM5_001757
155-58-8
rhapontin
rhaponticin ,
LMPK13090002
MLS002207294
smr001306806
chebi:8824 ,
CHEMBL109266
HMS503I09
(2s,3r,4s,5s,6r)-2-[3-hydroxy-5-[(e)-2-(3-hydroxy-4-methoxyphenyl)ethenyl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
A809657
3-hydroxy-5-[2-(3-hydroxy-4-methoxyphenyl)vinyl]phenyl-beta-d-glucopyranoside
S9083
AKOS016034205
CCG-38881
(2s,3r,4s,5s,6r)-2-[3-hydroxy-5-[(e)-2-(3-hydroxy-4-methoxy-phenyl)vinyl]phenoxy]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol
.beta.-d-glucopyranoside, 3-hydroxy-5-[(1e)-2-(3-hydroxy-4-methoxyphenyl)ethenyl]phenyl
rhapontigenin glucoside
3,3 inverted exclamation marka,5-trihydroxy-4 inverted exclamation marka-methoxystilbene 3-o-|a-d-glucoside
3-hydroxy-5-((1e)-2-(3-hydroxy-4-methoxyphenyl)ethenyl)phenyl .beta.-d-glucopyranoside
rhapontin [mi]
SCHEMBL160068
GKAJCVFOJGXVIA-DXKBKAGUSA-N
AC-34809
Q-100184
rhaponiticin
n,n-bis(trimethylsilyl)-1,4-butanediamine
mfcd00010117
rhapontin, analytical standard
CHEBI:92176
SR-05000002217-2
sr-05000002217
(2s,3r,4s,5s,6r)-2-(3-hydroxy-5-(3-hydroxy-4-methoxystyryl)phenoxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
HY-N0671
rhaponticin,(s)
(2s,3r,4s,5s,6r)-2-(3-hydroxy-5-((e)-3-hydroxy-4-methoxystyryl)phenoxy)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
Q7320229
DTXSID201018153
CS-0009703
beta-d-glucopyranoside, 3-hydroxy-5-[(1e)-2-(3-hydroxy-4-methoxyphenyl)ethenyl]phenyl
3,3',5-trihydroxy-4'-methoxystilbene 3-o-beta-d-glucoside
ss-d-glucopyranoside, 3-hydroxy-5-[(1e)-2-(3-hydroxy-4-methoxyphenyl)ethenyl]phenyl
AS-77402
rose oxide (cis)
GLXC-13093
R0252

Research Excerpts

Effects

ExcerptReferenceRelevance
"Rhapontin has anti-inflammatory effect and anti-proliferative activity which is widely distributed in the medicinal plants of Rheum genus in China."( Protective role of rhapontin in experimental pulmonary fibrosis in vitro and in vivo.
Cao, J; Tao, L; Wei, W; Xie, H; Zhang, C; Zhang, M, 2017
)
1.5

Treatment

ExcerptReferenceRelevance
"Treatment with rhapontin for 2weeks resulted in an amelioration of the BLM-induced pulmonary fibrosis in rats with a lower Lox2, whereas a higher AMPK expression, with reductions of the pathological score, collagen deposition, TGF-β1, α-SMA, Lox2, and HIF-1α expressions in lung tissues at fibrotic stage at 100mg/kg."( Protective role of rhapontin in experimental pulmonary fibrosis in vitro and in vivo.
Cao, J; Tao, L; Wei, W; Xie, H; Zhang, C; Zhang, M, 2017
)
1.12

Bioavailability

ExcerptReferenceRelevance
" However, there is no information describing the pharmacokinetics, bioavailability and metabolism of rhaponticin after intravenous administration."( Pharmacokinetics, bioavailability and metabolism of rhaponticin in rat plasma by UHPLC-Q-TOF/MS and UHPLC-DAD-MSn.
Bai, X; Cheng, XL; Lin, RC; Su, Q; Tan, XJ; Zhao, YY, 2012
)
0.38
"UHPLC-Q-TOF/MS and UHPLC-multistage tandem MS methods were developed for the pharmacokinetics, bioavailability and metabolism of rhaponticin in rats."( Pharmacokinetics, bioavailability and metabolism of rhaponticin in rat plasma by UHPLC-Q-TOF/MS and UHPLC-DAD-MSn.
Bai, X; Cheng, XL; Lin, RC; Su, Q; Tan, XJ; Zhao, YY, 2012
)
0.38
"The present pharmacokinetics, bioavailability and metabolism studies of rhaponticin will provide helpful information for development of suitable dosage forms and clinical references on rational administration."( Pharmacokinetics, bioavailability and metabolism of rhaponticin in rat plasma by UHPLC-Q-TOF/MS and UHPLC-DAD-MSn.
Bai, X; Cheng, XL; Lin, RC; Su, Q; Tan, XJ; Zhao, YY, 2012
)
0.38
" These pharmacokinetic, bioavailability and metabolism studies of RH will provide helpful information for the development of suitable dosage forms and clinical references on rational administration."( A simple and rapid spectrofluorimetric method for determining the pharmacokinetics and metabolism of rhaponticin in rat plasma, feces and urine using a cerium probe.
Sun, Y; Yang, X; Zhao, Y,
)
0.13
" However, its poor solubility and bioavailability restricted the clinical application greatly."( Enhanced pharmacokinetics and anti-tumor efficacy of PEGylated liposomal rhaponticin and plasma protein binding ability of rhaponticin.
Sun, Y; Zhao, Y, 2012
)
0.38

Dosage Studied

ExcerptRelevanceReference
"The present pharmacokinetics, bioavailability and metabolism studies of rhaponticin will provide helpful information for development of suitable dosage forms and clinical references on rational administration."( Pharmacokinetics, bioavailability and metabolism of rhaponticin in rat plasma by UHPLC-Q-TOF/MS and UHPLC-DAD-MSn.
Bai, X; Cheng, XL; Lin, RC; Su, Q; Tan, XJ; Zhao, YY, 2012
)
0.38
" These pharmacokinetic, bioavailability and metabolism studies of RH will provide helpful information for the development of suitable dosage forms and clinical references on rational administration."( A simple and rapid spectrofluorimetric method for determining the pharmacokinetics and metabolism of rhaponticin in rat plasma, feces and urine using a cerium probe.
Sun, Y; Yang, X; Zhao, Y,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (10)

RoleDescription
anti-inflammatory agentAny compound that has anti-inflammatory effects.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
neuroprotective agentAny compound that can be used for the treatment of neurodegenerative disorders.
EC 2.3.1.85 (fatty acid synthase) inhibitorAn EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor that interferes with the action of fatty acid synthase (EC 2.3.1.85), a multi-enzyme protein involved in fatty acid synthesis.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
angiogenesis inhibitorAn agent and endogenous substances that antagonize or inhibit the development of new blood vessels.
hypoglycemic agentA drug which lowers the blood glucose level.
anti-allergic agentA drug used to treat allergic reactions.
antilipemic drugA substance used to treat hyperlipidemia (an excess of lipids in the blood).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
rhaponticinA stilbenoid that is rhapontigenin substituted at position 3 by a beta-D-glucosyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID132501Inhibitory activity against nitric oxide production in LPS-activated mouse peritoneal macrophages2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Effects of stilbene constituents from rhubarb on nitric oxide production in lipopolysaccharide-activated macrophages.
AID1354544Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced IL6 expression at 30 uM after 24 hrs by ELISA2018Journal of natural products, 05-25, Volume: 81, Issue:5
Natural Stilbenoids Have Anti-Inflammatory Properties in Vivo and Down-Regulate the Production of Inflammatory Mediators NO, IL6, and MCP1 Possibly in a PI3K/Akt-Dependent Manner.
AID1354543Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced nitric oxide production at 30 uM after 24 hrs by Griess assay2018Journal of natural products, 05-25, Volume: 81, Issue:5
Natural Stilbenoids Have Anti-Inflammatory Properties in Vivo and Down-Regulate the Production of Inflammatory Mediators NO, IL6, and MCP1 Possibly in a PI3K/Akt-Dependent Manner.
AID722709Toxicity in FR-positive human KB cells implanted Balb/c mouse assessed as gross toxicity at 2 umol/kg, iv TIW 2 week schedule2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Synthesis and biological evaluation of a folate-targeted rhaponticin conjugate.
AID1081911Antifungal activity against Botryotinia fuckeliana assessed as growth inhibition after 72 hr by NCCLS M27-A broth microdilution method2011Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5
Biological activity of peanut (Arachis hypogaea) phytoalexins and selected natural and synthetic Stilbenoids.
AID722711Half life in human serum at 37 degC2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Synthesis and biological evaluation of a folate-targeted rhaponticin conjugate.
AID1081919Octanol-water partition coefficient, log P of the compound by HPLC analysis2011Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5
Biological activity of peanut (Arachis hypogaea) phytoalexins and selected natural and synthetic Stilbenoids.
AID1667360Inhibition of alpha-glucosidase (unknown origin) using p-NPG as substrate by spectrophotometric analysis2020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Tetra-aryl cyclobutane and stilbenes from the rhizomes of Rheum undulatum and their α-glucosidase inhibitory activity: Biological evaluation, kinetic analysis, and molecular docking simulation.
AID1824689Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1488475Inhibition of recombinant human ACE at 100 uM using Mca-R-P-PG-F-S-A-F-K(Dnp)-OH as substrate measured every 2 mins for 8 mins by fluorescence assay2017Bioorganic & medicinal chemistry letters, 08-15, Volume: 27, Issue:16
Discovery of a potent angiotensin converting enzyme inhibitor via virtual screening.
AID1374189Estrogenic activity at ERalpha/ERbeta (unknown origin) expressed in human HepG2 cells co-expressing ERE-dependent promoter assessed as increase in ER-mediated transcriptional activation at 1 uM incubated for 24 hrs by luciferase reporter gene assay relati2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Estrogenic activity of constituents from the rhizomes of Rheum undulatum Linné.
AID722708In vivo antitumor activity against FR-positive mouse M109 cells implanted in Balb/c mouse assessed as decrease in tumor volume at 2 umol/kg, iv treated 33 days after implantation for TIW 3 week schedule2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Synthesis and biological evaluation of a folate-targeted rhaponticin conjugate.
AID1824692Antiproliferative activity against human HCCLM3 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1824731Inhibition of pyruvate carboxylase in human HCCLM3 cell lysate measured upto 24 hrs by PC assay kit2022Journal of medicinal chemistry, 01-13, Volume: 65, Issue:1
Identification of Pyruvate Carboxylase as the Cellular Target of Natural Bibenzyls with Potent Anticancer Activity against Hepatocellular Carcinoma via Metabolic Reprogramming.
AID1081915Antifungal activity against Phomopsis obscurans assessed as growth inhibition at 30 uM after 144 hr by NCCLS M27-A broth microdilution method2011Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5
Biological activity of peanut (Arachis hypogaea) phytoalexins and selected natural and synthetic Stilbenoids.
AID1354545Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced MCP1 expression at 30 uM after 24 hrs by ELISA2018Journal of natural products, 05-25, Volume: 81, Issue:5
Natural Stilbenoids Have Anti-Inflammatory Properties in Vivo and Down-Regulate the Production of Inflammatory Mediators NO, IL6, and MCP1 Possibly in a PI3K/Akt-Dependent Manner.
AID134177Compound (at 100 uM) was tested for inhibition against nitric oxide production in LPS-activated mouse peritoneal macrophages2000Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4
Effects of stilbene constituents from rhubarb on nitric oxide production in lipopolysaccharide-activated macrophages.
AID722714Antitumor activity against FR-positive human KB cells assessed as decrease in cell viability measured after 48 hrs by MTT proliferation assay2013Bioorganic & medicinal chemistry, Jan-01, Volume: 21, Issue:1
Synthesis and biological evaluation of a folate-targeted rhaponticin conjugate.
AID1374190Estrogenic activity at ERalpha/ERbeta (unknown origin) expressed in human HepG2 cells co-expressing ERE-dependent promoter assessed as increase in ER-mediated transcriptional activation at 10 uM incubated for 24 hrs by luciferase reporter gene assay relat2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Estrogenic activity of constituents from the rhizomes of Rheum undulatum Linné.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1354555Inhibition of PI3K/Akt in mouse J774 cells assessed as reduction in LPS-induced Akt phosphorylation at Ser473 at 100 uM after 4 hrs by Western blot analysis2018Journal of natural products, 05-25, Volume: 81, Issue:5
Natural Stilbenoids Have Anti-Inflammatory Properties in Vivo and Down-Regulate the Production of Inflammatory Mediators NO, IL6, and MCP1 Possibly in a PI3K/Akt-Dependent Manner.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID338266Inhibition of Ca2+ ATPase activity in human red blood cells at 1600 uM by spectrophotometry1994Journal of natural products, Dec, Volume: 57, Issue:12
Novel Ca(2+)-ATPase inhibitors from the dried root tubers of Polygonum Multiflorum.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (60)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (10.00)18.7374
1990's3 (5.00)18.2507
2000's13 (21.67)29.6817
2010's30 (50.00)24.3611
2020's8 (13.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.38 (24.57)
Research Supply Index4.17 (2.92)
Research Growth Index4.97 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.13%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other62 (96.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]